切换至 "中华医学电子期刊资源库"
高级检索
中华眼科医学杂志(电子版)

中华眼科医学杂志(电子版) ›› 2023, Vol. 13 ›› Issue (02) : 99 -103. doi: 10.3877/cma.j.issn.2095-2007.2023.02.007

综述

正电子发射断层扫描－计算机断层显像在眼附属器淋巴瘤临床中应用的研究进展
张璇, 柳睿, 李静, 马建民†()   
  1. 271000　青岛大学附属泰安市中心医院眼科
    100730　首都医科大学附属北京同仁医院　北京同仁眼科中心　北京市眼科学与视觉科学重点实验室
  • 收稿日期:2021-08-10 出版日期:2023-04-28
  • 通信作者: 马建民
  • 基金资助:
    北京市科技新星计划交叉合作项目(20220484218); 泰安市科技创新发展项目(2021NS207)

Progress in the clinical application of the positron emission tomography-computed tomography imaging in ocular adnexal lymphoma

Xuan Zhang, Rui Liu, Jing Li, Jianmin Ma†()   

  1. Department of Ophthalmology, The Affiliated Taian City Central Hospital of Qingdao University, Taian 271000, China
    Beijing Tongren Eye Center, Beijing Tongren Hospital, Capital Medical University, Beijing Key Laboratory of Ophthalmology and Visual Science, Beijing 100730, China
  • Received:2021-08-10 Published:2023-04-28
  • Corresponding author: Jianmin Ma
全文 ( ) 下载PDF ( ) 导出引用
引用本文：

张璇, 柳睿, 李静, 马建民. 正电子发射断层扫描－计算机断层显像在眼附属器淋巴瘤临床中应用的研究进展[J]. 中华眼科医学杂志(电子版), 2023, 13(02): 99-103.

Xuan Zhang, Rui Liu, Jing Li, Jianmin Ma. Progress in the clinical application of the positron emission tomography-computed tomography imaging in ocular adnexal lymphoma[J]. Chinese Journal of Ophthalmologic Medicine(Electronic Edition), 2023, 13(02): 99-103.

眼附属器淋巴瘤是发生于成人眼附属器常见的恶性肿瘤，其病理类型复杂，临床特征多样，可以发生在任何年龄段。正电子发射断层扫描－计算机断层显像(PET－CT)可对眼附属器淋巴瘤初始分期和治疗策略的制定提供依据，亦可用于评估其疗效及预后。本文中笔者就PET－CT在眼附属器淋巴瘤临床中应用的进展作一综述。

关键词: 正电子发射断层扫描－计算机断层成像, 淋巴瘤, 眼附属器, 诊断与预后

Ocular adnexal lymphoma is a common malignant tumor of adult ocular adnexa, which has complex pathological types and various clinical features and can occur at any age.The positron emission tomography-computed tomography(PET-CT) can provide the evidence for the formulation of initial staging and treatment strategy, which is also used to evaluate the efficacy and prognosis of ocular adnexal lymphoma. The progress of PET-CT in the clinical application of ocular adnexal lymphoma was reviewed in this paper.

Key words: Positron emission tomography-computed tomography, Lymphoma, Ocular adnexa, Diagnosis and prognosis
图2 眼附属器淋巴瘤转移患者的正电子发射断层扫描－计算机断层成像　图2A示结膜淋巴瘤转移；　图2B示颌下腺、腮腺转移
[1]
Mugnaini EN, Ghosh N. Lymphoma[J]. Prim Care, 2016, 43(4): 661－675.
[2]
Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms[J]. Blood, 2016, 127(20): 2375－2390.
[3]
Shields JA, Shields CI, Scartozzi R. Survey of 1246 patients withorbital tumors and simulating lesions[J]. Ophthalmology, 2004, 111(5): 997－1008.
[4]
Ohtsuka K, Hashimoto M, Suzuki Y. A review of 244 orbital tumors in Japanese patients during a 21－year period: origins and locations[J]. Jpn J Ophthalmol, 2005, 49(1): 49－55.
[5]
何彦津，宋国祥，丁莹. 3476例眼眶占位病变的组织病理分类[J]. 中华眼科杂志，2002，38(7)：396－398.
[6]
游启生，李彬，周小鸽，等. 112例眼附属器淋巴增生性病变临床组织病理学初步分析[J]. 中华眼科杂志，2005，41(10)：871－876.
[7]
Feery JA, Fung CY, Zukerberg L, et al. Lymphoma of the ocular adnexa：a study of 353 cases[J]. Am J Surg Pathol, 2007, 31(2)：170－184.
[8]
胡轶，何为民. 眼附属器淋巴瘤的临床病理分析[J]. 国际眼科杂志，2019，19(6)：1082－1085.
[9]
Sniegowski MC, Roberts D, Bakhoum M, et al. Ocular adnexal lymphoma: validation of American Joint Committee on Cancer seventhedition staging guidelines[J]. Br J Ophthalmol, 2014, 98(9): 1255－1260.
[10]
Demirci H, Shields CL, Karatza EC, et al. Orbital lympho－proliferative tumors: analysis of clinical features and systemic involvement in 160 cases[J]. Ophthalmology, 2008, 115(9): 1626－1631.
[11]
Alkatan HM, Alaraj A, El－Khani A, et al. Ocular adnexal lymphoproliferative disorders in an ophthalmic referral center in Saudi Arabia[J]. Saudi J Ophthalmo, 2013, 27(3): 227－230.
[12]
Oh DE, Kim YD. Lymphoproliferative diseases of the ocular adnexa in Korea[J]. Arch Ophthalmol, 2007, 125(12): 1668－1673.
[13]
Coupland SE, Hellmich M, Auw－Haedrich C, et al. Prognostic valueof cell－cycle markers in ocular adnexal lymphoma: an assessment of 230 cases[J]. Graefes Arch Clin Exp Ophthalmol, 2004, 242(2): 130－145.
[14]
孙梅，马建民. 眼眶淋巴瘤流行病学特点[J]. 中华实验眼科杂志，2020，38(11)：979－982.
[15]
Schaffel R, Hedvat CV, Teruya－Feldstein J, et al. Prognostic impactof proliferative index determined by quantitative image analysis and the International Prognostic Index in patients with mantle cell lymphoma[J]. Ann Oncol, 2010, 21(1): 133－139.
[16]
White VA. Understanding and classification of ocular lymphomas[J]. Ocul Oncol Pathol, 2019, 5(6): 379－386.
[17]
Kim SE, Yang HJ, Yang SW. Effects of radiation therapy on the meibomian glands and dry eye in patients with ocular adnexal mucosa associated lymphoid tissue lymphoma[J]. BMC Ophthal－mol, 2020, 20(1): 24.
[18]
Kiesewetter B, Lukas J, Kuchar A, et al. Clinical features, treatment and outcome of mucosa－associated lymphoid tissue (MALT) lymphoma of the ocular adnexa: single center experience of 60 patients[J]. PLoS One, 2014, 9(7): e104004.
[19]
Pinnix CC, Dabaja BS, Milgrom SA, et al. Ultra－low－dose radiotherapy for definitive management of ocular adnexal B－cell lymphoma[J]. Head Neck, 2017, 39(6): 1095－1100.
[20]
Jakobiec FA. Ocular adnexal lymphoid tumors progress in need of clarification[J]. Am J Ophthalmol, 2008, 145: 941－950.
[21]
Stefanovic A, Lossos IS. Extranodal marginal zone lymphoma of the ocular adnexa[J]. Blood, 2009, 114: 501－510.
[22]
Coupland SE, White VA, Rootman J, et al. A TNM－based clinical staging system of ocular adnexal lymphomas [J]. Arch Pathol Lab Med, 2009, 133(8): 1262－1267.
[23]
Graue GF, Finger PT, Maher E, et al. Ocular adnexal lymphoma staging and treatment: American Joint Committee on Cancer versus Ann Arbor [J]. Eur J Ophthalmol, 2013, 23(3): 344－355.
[24]
Beyer T, Townsend DW, Blodgett TM. Dual－modality PET/CT tomography for clinical oncology[J]. Q J Nucl Med, 2002，46(1): 24－34.
[25]
Kalemaki MS, Karantanas AH, Exarchos D, et al. PET/CT and PET/MRI in ophthalmic oncology[J]. Int J Oncol, 2020, 56(2): 417－429.
[26]
张蕾，宋国祥．PET/CT在眼部肿瘤诊断中的应用[J]. 中华实验眼科杂志，2015，33: 380－384.
[27]
Finger PT, Chin K, Iacob CE. 18－Fluorine－Labelled 2－deoxy－2－fluoro－D－glucose positrone mission tomography/computed tomography standardised uptake values: a non－invasive biomarker for the risk of metastasis from choroidal melanoma[J]. Br J Ophthalmol, 2006, 90(10): 1263－1266.
[28]
Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of hodgkin and non－hodgkin lymphoma: the lugano classification[J]. J Clin Oncol, 2014, 32(27): 3059－3068.
[29]
Bunyaviroch T, Coleman RE. PET evalution of lung cancer[J]. J Nucl Med, 2006, 47(3): 451－469.
[30]
Blodgett T, Meltzer CC, Townsend DW. PET/CT: form and function[J]. Radiology, 2007, 242(2): 360－385.
[31]
Fletcher JW, Djulbegovic B, Soares HP, et al. Recommen－dations on the use of 18F－FDG PET in oncology[J]. J Nucl Med, 2008, 49(3): 480－508.
[32]
Elstrom R, Guan L, Baker G, et al. Utility of FDG－PET scanning in lymphoma by WHO classification[J]. Blood, 2003, 101: 3875－3876.
[33]
Wöhrer S, Jaeger U, Kletter K, et al. 18F－fluoro－deoxy－glucose positron emission tomography (18F－FDG－PET) visualizesfollicular lymphoma irrespective of grading[J]. Ann Oncol, 2006, 17(5): 780－784.
[34]
Seam P, Juweid ME, Cheson BD. The role of FDG－PET scans in patients with lymphoma[J]. Blood, 2007, 110(10): 3507－3516.
[35]
Tsukamoto N, Kojima M, Hasegawa M, et al. The usefulness of 18F－fluorodeoxyglucose positron emission tomography(18F－FDG－PET )and a comparison of 18F－FDG－PET with 67gallium scintigraphy in the evaluation of lymphoma: relationto histologic subtypes based on the World Health Organization classification[J]. Cancer, 2007, 110: 652－659.
[36]
Karam M, Novak L, CyriacJ, et al. Role of fluorine－18 fluoro－deoxyglucose positron emission tomography scan in the evaluation and follow－up of patients with low－grade lymphomas[J]. Cancer, 2006, 107(1): 175－183.
[37]
Burrell SC, van－den－Abbeele AD. 2－Deoxy－2－[F－18]fluoro－D－glucose－positron emission tomography of the head and neck: an atlas of normal uptake and variants[J]. Mol Imaging Biol, 2005, 7(3): 244－256.
[38]
王观筠，杨晖，陈佳欣，等. 眼附属器淋巴瘤18F－FDG PET－CT的代谢特征及其与临床分期的相关性[J]. 首都医科大学学报，2021，42(1)：21－25.
[39]
Jiang P, Liao SS, Lan XL, et al. Whole body positron emission tomography－computed tomography(PET－CT) in the evaluation of ophthalmic tumors[J]. Current Medical Science, 2018, 38(2): 310－317.
[40]
Zanni M, Romsee GM, Servois V, et al. Value of 18F－FDG PET scan in staging of ocular adnexal lymphomas: a large single－center experience[J]. Hematology, 2012, 17(2): 76－84.
[41]
Park HL, Oh JH, Park SY, et al. Role of 18F－FDG PET－CT in nonconjunctival origin ocular adnexal mucosa－associated lymphoid tissue (MALT) lymphomas[J]. EJNMMI Res, 2019, 9: 99.
[42]
Suga K, Yasuhiko K, Hiyama A, et al. 18F－FDG PET－CT findings in a patient with bilateral orbital and gastric mucosa－associated lymphoid tissue lymphomas[J]. Clin Nucl Med, 2009, 34(9): 589－593.
[43]
Klingenstein A, Garip－Kuebler A, Mueller－Lisse UG, et al. Combined positron emission tomography－computed tomography for diagnosis and monitoring of orbital adnexal lymphoma[J]. Acta Ophthalmol, 2018, 96: 712－717.
[44]
Stefanovic A, Lossos IS. Extranodal marginal zone lymphoma of the ocular adnexa[J]. Blood, 2009, 114(3): 501－510.
[45]
Rasmussen JH, Vogelius IR, Fischer BM, et al. Prognostic value of 18F－fludeoxyglucose uptake in 287 patients with head and neck squamous cell carcinoma[J]. Head Neck, 2015, 37(9)：1274－1281.
[46]
郑营营，杨忠毅. PET－CT显像在头颈部肿瘤中的临床应用进展[J]. 中国癌症杂志，2017，27(6)：425－431.
[47]
Albano D, Giubbini R, Bertagna F. 18F－FDG PET－CT in splenic marginal zone lymphoma[J]. Abdom Radiol(NY), 2018, 43(10): 2721－2727.
[48]
Wang W, Ni X, Tang T, et al. The role of 18F－FDG PET－CT in diagnosis and treatment evaluation for ocular adnexal mucosa－associated lymphoid tissue lymphoma[J]. Br J Radiol, 2022, PMID: 34919440.
[49]
Fujii H, Tanaka H, Nomoto Y, et al. Usefulness of 18F－FDG PET－CT for evaluating response of ocular adnexal lymphoma to treatment[J]. Medicine, 2018, 97(17): e0543.
[50]
Yildirim－Poyraz N, Ozdemir E, Basturk A, et al. PET－CT findings in a case with FDG－avid disseminated lacrimal gland MALToma with sequential development of large B－cell lymphoma and gastric MALToma[J]. Clin Nucl Med, 2015, 40(2): 141－145.
[51]
Saindane AM. Pitfalls in the staging of cervical lymph node metastasis[J]. Neuroimaging Clin N Am, 2013, 23(1): 147－166.
[52]
Treglia G, Zucca E, Sadeghi R, et al. Detection rate of fluorine－18－fluorodeoxyglucose positron emission tomography in patients with marginal zone lymphoma of MALT type: a meta－analysis[J]. Hematol Oncol, 2015, 33(3): 113－124.
[1] 彭婵娟, 孔祥凯, 吴军舟, 彭帅羚, 徐栋, 杨琛. 超声分型对原发性甲状腺淋巴瘤的诊断价值[J]. 中华医学超声杂志（电子版）, 2022, 19(05): 447-453.
[2] 给汝拉丛, 赵捷颖, 闫静文, 庄华. 脾淋巴瘤与脾转移癌的临床及超声特征分析[J]. 中华医学超声杂志（电子版）, 2022, 19(05): 434-439.
[3] 刘婧, 袁馥梅, 郝尔娃, 刘婧, 王薇, 曹海霞. CHU9D与EQ-5D-Y量表评估急性淋巴细胞白血病患儿健康效用值比较[J]. 中华妇幼临床医学杂志(电子版), 2022, 18(02): 213-219.
[4] 李玉静, 陈七一, 谢汝明, 陈步东. 获得性免疫缺陷综合征相关原发性中枢神经系统淋巴瘤的预后研究[J]. 中华实验和临床感染病杂志(电子版), 2023, 17(03): 200-208.
[5] 崔贵香, 丁晓燕, 褚盈晖, 孙代, 吴海燕, 陈京龙. 57例人类免疫缺陷病毒感染合并Burkkit淋巴瘤患者的临床分析[J]. 中华实验和临床感染病杂志(电子版), 2023, 17(02): 102-109.
[6] 李协照, 徐桂彬, 袁耀基, 蔡志煅, 朱锐, 梁斯扬, 庄浩铨, 李逊. 上尿路结石合并血液肿瘤的诊治体会（附13例报告）[J]. 中华腔镜泌尿外科杂志(电子版), 2021, 15(06): 493-496.
[7] 杨美, 简亿, 方莉, 余枝娟, 张建勇. 肺鳞癌合并鼻部弥漫大B细胞淋巴瘤一例[J]. 中华肺部疾病杂志(电子版), 2022, 15(06): 926-928.
[8] 何继强, 任安伟, 王飞. 周围型肺癌CT特征与PCNA、VEGF及Bcl-2表达水平的相关性[J]. 中华肺部疾病杂志(电子版), 2022, 15(04): 527-529.
[9] 苏春艳, 吴涛, 毛东锋, 刘文慧, 鱼玲玲, 白海. 异基因造血干细胞移植治疗急性混合细胞白血病后继发外周T细胞淋巴瘤1例[J]. 中华细胞与干细胞杂志(电子版), 2022, 12(05): 289-292.
[10] 韦远, 徐西占, 梁庆丰. 免疫性眼表疾病眼表菌群的研究进展[J]. 中华眼科医学杂志(电子版), 2023, 13(01): 55-59.
[11] 薛友余, 王伟, 陶勇, 冯婧. 玻璃体腔注射甲氨蝶呤治疗原发性眼内淋巴瘤的临床研究[J]. 中华眼科医学杂志(电子版), 2022, 12(02): 88-93.
[12] 贾炜, 王海燕, 王茹, 陶勇, 黄轩. 原发性玻璃体视网膜淋巴瘤诊断面临的机遇和挑战[J]. 中华眼科医学杂志(电子版), 2022, 12(02): 65-69.
[13] 吴钰娴, 冯亚园, 霍雷, 贾宁阳, 张娟. 原发性肝脏淋巴瘤的影像学诊断价值研究[J]. 中华消化病与影像杂志(电子版), 2023, 13(05): 349-353.
[14] 于冬洋, 韩雷, 单奔, 柳勇, 赵正宇, 马乐艳. 基于CT增强的直方图对腮腺多形性腺瘤与腺淋巴瘤的应用价值[J]. 中华消化病与影像杂志(电子版), 2022, 12(05): 291-295.
[15] 李婧娴, 王燕婴, 李佼, 李利红. 非霍奇金B细胞淋巴瘤患者化疗后中性粒细胞缺乏相关危险因素及其与疗效的关系[J]. 中华临床医师杂志(电子版), 2022, 16(10): 982-988.
阅读次数
全文


摘要

版权所有 中华医学会 中华医学电子音像出版社有限责任公司  京ICP备14006079号-1  网络出版服务许可证：(署)网出证(京)字第075号